/PRNewswire/ Alkermes plc (Nasdaq: ALKS) today announced plans to present data from the ARTISTRY-1 clinical trial for nemvaleukin alfa (nemvaleukin), the.
- ARTISTRY-1 Data Showed Anti-Tumor Activity of Nemvaleukin, as a Monotherapy and in Combination with Pembrolizumab, in Multiple Tumor Types - - Company to Host Investor Webcast on June
Four New York University faculty have been elected to the National Academy of Sciences: Fedor A. Bogomolov and Michael J. Shelley, professors in the Courant Institute of Mathematical Sciences; sociologist Paul DiMaggio; and Benjamin G. Neel, director
/PRNewswire/ Benjamin G. Neel, MD, PhD, director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone Health and an internationally renowned.
- Final Dataset from ARTISTRY-1 Clinical Trial to be Featured in an Oral Presentation - - Trial-in-Progress Posters From ARTISTRY-3, ARTISTRY-6 and ARTISTRY-7 Clinical Trials to be Presented